Volume 70, Issue 4 pp. 435-440
Full Access

Replacement therapy for a homozygous protein C deficiency-state using a concentrate of human protein C and S

Thomas Vukovich

Corresponding Author

Thomas Vukovich

Department of Medical Physiology, University of Vienna, Vienna, Austria

Dr Thomas Vukovich, Department of Medical Physiology, University of Vienna, Schwarzspanierstr. 17, A-1090 Vienna, Austria.Search for more papers by this author
Karin Auberger

Karin Auberger

Children's Hospital, University of Munich, Munich, F.R.G.

Search for more papers by this author
Jochen Weil

Jochen Weil

Children's Hospital, University of Munich, Munich, F.R.G.

Search for more papers by this author
Hartmut Engelmann

Hartmut Engelmann

Children's Hospital, University of Munich, Munich, F.R.G.

Search for more papers by this author
Paul Knöbl

Paul Knöbl

Department of Medical Physiology, University of Vienna, Vienna, Austria

Search for more papers by this author
Hans Beat Hadorn

Hans Beat Hadorn

Children's Hospital, University of Munich, Munich, F.R.G.

Search for more papers by this author
First published: December 1988
Citations: 44

Abstract

A severe congenital deficiency of protein C was diagnosed in a 10-month-old girl who had been suffering from skin necrosis since the age of 7 months. The patient was treated initially with fresh frozen plasma, 10 ml per kg body weight, every 24 h. Following treatment, the mean plasma level of protein C was 0.1 U/ml after 30 min and less than 0.02 U/ml after 24 h. The child was then treated with a concentrate of human protein C and S, 100 U protein C per kg body weight, given every 48 h for a period of 9 months. The mean plasma level of protein C was 0.93 U/ml 30 min after administration of the concentrate and 0.13 and 0.08 U/ml after 24 and 48 h, respectively. The mean post-transfusional in vivo recovery of protein C was 44% and the half life was 8.3 h. The mean plasma level of ‘free’protein S increased from 1.1 to 2.2 U/ml after administration of the concentrate. There was no increase in ‘bound’protein S. The in vivo recovery of ‘free’protein S was 49% and the half life was about 17 h. Since the start of this replacement therapy using a human protein C and S concentrate, the patient has not developed any thromboembolic complications. These results indicate the therapeutic value of human protein C and S concentrate in the treatment of severe protein C deficiency.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.